HC Wainwright Expects Higher Earnings for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Keros Therapeutics in a research note issued on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($4.62) per share for the year, up from their previous forecast of ($5.12). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2026 earnings at ($1.49) EPS, FY2027 earnings at ($6.39) EPS, FY2028 earnings at ($5.72) EPS, FY2029 earnings at ($3.40) EPS and FY2030 earnings at ($0.96) EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%.

Several other analysts have also recently issued reports on KROS. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Finally, Leerink Partners decreased their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Stock Down 2.5%

NASDAQ:KROS opened at $9.99 on Thursday. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55. The company has a fifty day simple moving average of $10.64 and a two-hundred day simple moving average of $12.46. The company has a market cap of $197.72 million, a price-to-earnings ratio of -2.70 and a beta of 0.99.

Insider Buying and Selling

In other Keros Therapeutics news, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 9,767 shares of the company’s stock, valued at $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,425 shares of company stock worth $89,994. Corporate insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KROS. Vanguard Group Inc. lifted its stake in Keros Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after purchasing an additional 87,129 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Keros Therapeutics by 26.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock valued at $15,645,000 after purchasing an additional 161,336 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the last quarter. Federated Hermes Inc. increased its stake in Keros Therapeutics by 27.3% in the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock valued at $13,330,000 after purchasing an additional 140,564 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Keros Therapeutics by 282.5% during the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after purchasing an additional 436,986 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.